Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI0ED3
|
|||
| Drug Name |
SYD985
|
|||
| Synonyms |
(vic)-trastuzumab duocarmazine
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 3 | [1] | |
| Company |
Byondis
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03262935) A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health. | |||
| REF 2 | Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.